2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149731
    M1/M2/M4 muscarinic agonist 2 98%
    M1/M2/M4 muscarinic agonist 2 (compound 43) is a muscarinic mAChR M1/M2/M4 agonist with EC50s of 30 nM, 200 nM and 6.2 nM, respectively.
    M1/M2/M4 muscarinic agonist 2
  • HY-149732
    M1/M4 muscarinic agonist 3 2640109-30-2 98%
    M1/M4 muscarinic agonist 3 (compound 44) is a muscarinic mAChR M1/M4 agonist with EC50s of 31 nM and 9.3 nM, respectively.
    M1/M4 muscarinic agonist 3
  • HY-149733
    M1/M2/M4 muscarinic agonist 3 2640109-28-8 98%
    M1/M2/M4 muscarinic agonist 3 (compound 45) is a muscarinic mAChR M1/M2/M4 agonist with EC50s of 3.2 nM, 32 nM and 1.7 nM, respectively.
    M1/M2/M4 muscarinic agonist 3
  • HY-149764
    Aβ42 agonist-2 6314-40-5 99.92%
    Aβ42 agonist-2 (compound 7b) is a small molecule compound that can promote Aβ42 aggregation. Aβ42 agonist-2 can interact with Aβ42 oligomers and pentamers to promote nontoxic aggregate self-assembly and rapid fibril formation. Aβ42 agonist-2 prevents Aβ42-induced cytotoxicity in HT22 hippocampal neuronal cells.
    Aβ42 agonist-2
  • HY-149776
    RGH-560 2408799-43-7 98%
    RGH-560 (compound 53) shows highly advanced α7 nAChR positive modulator properties and favorable physicochemical features. RGH-560 has robust procognitive in vivo potential. RGH-560 can be used to study Scopolamine (HY-N0296) -induced amnesia in mice.
    RGH-560
  • HY-149817
    AChE-IN-29 98%
    AChE-IN-29, 3-OH pyrrolidine derivative, is an cholinesterase (ChE) inhibitor. AChE-IN-29 has cholinesterase inhibitory activity for hAChE, eeAChE and eqBChE with IC50 values of 0.25 μM, 0.23 μM and 0.72 μM, respectively. AChE-IN-29 can be used for the research of Alzheimer's disease.
    AChE-IN-29
  • HY-149820
    MAO-B-IN-22 2902600-76-2 98%
    MAO-B-IN-22 (compound 6h) is a potent MAO-B inhibitor with an IC50 of 0.014 μM. MAO-B-IN-22 has high antioxidant activity, good metal chelating ability, proper BBB permeability and significant neuroprotective effect.
    MAO-B-IN-22
  • HY-149823
    TRPV4 antagonist 4 2918803-89-9 98%
    TRPV4 antagonist 4 is a potent TRPV4 antagonist with an IC50 value of 22.65 nM. TRPV4 antagonist 4 inhibits TRPV4 current. TRPV4 antagonist 4 shows protective effects on acute lung injury.
    TRPV4 antagonist 4
  • HY-149853
    AD186 98%
    AD186 is a potent and selective S1R agonist with Kis of 2.7, 27 nM for S1R and S2R, respectively. AD186 fully reverses the antiallodynic effect of BD-1063 (HY-18101A).
    AD186
  • HY-149854
    AB21 3026677-23-3 98%
    AB21 is a potent and selective S1R antagonist with Kis of 13, 102 nM for S1R and S2R. AB21 has the effect of reducing mechanical hypersensitivity.
    AB21
  • HY-149859
    HDAC-IN-58 2071224-39-8 98%
    HDAC-IN-58 is a HDAC inhibitor. HDAC-IN-58 has HDAC6-specific inhibition activity with an IC50 value of 2.06 nM. HDAC-IN-58 can be used for the research of chronic diseases, including neurodegenerative and psychiatric conditions.
    HDAC-IN-58
  • HY-149863
    DDO-8926 3017181-08-4 98%
    DDO-8926 is a potent and selective BET inhibitor that can significantly reduce mechanical hypersensitivity by inhibiting the expression of pro-inflammatory cytokines and reducing excitability for neuropathic pain research.
    DDO-8926
  • HY-149888
    AChE-IN-31 1325209-07-1 98%
    AChE-IN-31 (compound 1) is a non-competitive AChE inhibitor with potential for the study of Alzheimer's disease.
    AChE-IN-31
  • HY-149933
    AM841 871978-21-1 98%
    AM841 is a high-affinity electrophilic ligand. AM841 interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. AM841 reduces Forskolin (HY-15371)-stimulated cAMP accumulation. AM841 also slows gastrointestinal motility.
    AM841
  • HY-149941
    hNTS1R agonist-1 98%
    hNTS1R agonist-1 (Compound 10) is a BBB permeable hNTS1R full agonist (Ki: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent.
    hNTS1R agonist-1
  • HY-149975
    AMPA receptor modulator-4 2917551-59-6 98%
    AMPA receptor modulator-4, a 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide (BTD), is an orally active positive allosteric modulator of the AMPA receptors (AMPAR PAMs). AMPA receptor modulator-4 can cross the blood-brain barrier. AMPA receptor modulator-4 increases the cognition performance and improves working memory performance in mice.
    AMPA receptor modulator-4
  • HY-149984
    MAO-B-IN-21 2956426-18-7 98%
    MAO-B-IN-21 is an excellent MAO-B inhibitor with antioxidant activity and anti-Aβ aggregation activity. MAO-B-IN-21 also exhibits metal-ion chelating ability, anti-neuroinflammation (NO, TNF-α), neuroprotective activity and BBB permeability. MAO-B-IN-21 significantly improves the memory and cognitive impairment in Aβ1-42 induced Alzheimer's disease mice model.
    MAO-B-IN-21
  • HY-149993
    hBChE-IN-2 2923366-36-1 98%
    hBChE-IN-2 (compound 15d) is a butyrylcholinesterase (BChE) inhibitor (IC50 of 0.62 μM) and a cannabinoid receptor 2 (CB2R) agonist. hBChE-IN-2 has neuroprotection activities.
    hBChE-IN-2
  • HY-149994
    DS43260857 1612158-07-2 98%
    DS43260857 is a potentNaV1.7inhibitor, which has a high inhibitory effect on both human and mouse NaV1.7. The IC50 values of DS43260857 for hNaV1.1, hNaV1.5, hNaV1.7, mNaV1.7 are 6.6, 14, 0.015 and 0.061 μM, respectively.
    DS43260857
  • HY-150030
    CB1/2 agonist 4 2772949-38-7 98%
    CB1/2 agonist 4 is a full CB1 agonist and CB2 partial agonist with EC50 values of 15.09 nM and 1.16 nM, respectively. CB1/2 agonist 4 also has hCB1 and hCB2 receptor affinities with Ki values of 1.1 nM and 4.2 nM, respectively. CB1/2 agonist 4 has a significant antinociceptive activity, and also can activate cannabinoid and TRPV1 receptor with values of IC50 and EC50 is 0.8 μM and 0.12 μM, respectively.
    CB1/2 agonist 4
Cat. No. Product Name / Synonyms Application Reactivity